Skip to main content
. Author manuscript; available in PMC: 2014 Mar 26.
Published in final edited form as: Mol Cancer Ther. 2009 Aug 11;8(8):2461–2469. doi: 10.1158/1535-7163.MCT-08-0857

Table 2.

Biological characteristics and sensitivity to MLN8054 in human neuroblastoma cell lines

Cell line Origin MYCN p53 status Cell type IC50 of MLN8054 (µmol/L)
SK-N-SH NB tumor SC WT N + S 0.46 ± 0.01 (2)
SH-SY5Y-Luc NB tumor SC WT N 0.24 ± 0.02 (4)
IMR-32 NB tumor A WT N 0.30 ± 0.08 (2)
LAN-1 NB tumor A Null N 0.67 ± 0.04 (4)
JF NB tumor A N/D N 0.26 ± 0.06 (3)
SH-EP NB tumor SC WT S 0.92 (1)
NB19 NB tumor A WT S 0.50 (1)
SMS-KCN NB tumor A N/D S 2.77 ± 0.18 (2)
SK-N-AS NB tumor SC mt S 4.11 ± 1.03 (2)
MCF-10A Breast normal epithelial WT 12.92 (1)
MCF-7 Breast tumor WT 0.44 (1)

NOTE: Numbers represent average ± SD IC50 derived from a Cell Counting Kit-8 proliferation assay. Values in parentheses represent the number of experiments completed for each cell line.

Abbreviations: NB, neuroblastoma; SC, single copy; A, amplified; WT, wild-type; mt, mutated; N/D, not described; N, neuroblastic; S, substrate adherent.

HHS Vulnerability Disclosure